For: | Lai RM, Lin S, Wang MM, Li N, Zhou JH, Lin XY, Chen TB, Zhu YY, Zheng Q. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J Hepatol 2023; 15(8): 964-972 [PMID: 37701915 DOI: 10.4254/wjh.v15.i8.964] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v15/i8/964.htm |
Number | Citing Articles |
1 |
Yu-Tong Sun, Qian-Qian Chen. Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients. World Journal of Hepatology 2024; 16(1): 109-111 doi: 10.4254/wjh.v16.i1.109
Abstract(126) |
Core Tip(139) |
Full Article(HTML)(466)
|
Full Article with Cover (PDF)-11079K(30)
|
Full Article (Word)-109K(10)
|
Audio-243K(0)
|
Peer-Review Report-215K(14)
|
Answering Reviewers-19K(14)
|
Full Article (PDF)-325K(36)
|
Full Article (XML)-24K(27)
|
Times Cited (0)
|
Total Visits (1200)
|
Open
|
2 |
Pin-Nan Cheng, Ming-Lung Yu. Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer. Clinical and Molecular Hepatology 2024; 30(2): 144 doi: 10.3350/cmh.2024.0115
|
3 |
Danqing Hu, Peng Wang, Xiaojing Wang, Xue Hu, Da Huang, Weiming Yan, Dong Xi, Meifang Han, Qin Ning, Hongwu Wang. The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis. Heliyon 2024; 10(7): e28653 doi: 10.1016/j.heliyon.2024.e28653
|